Yusuf Yazıcı
About
Yusuf Yazıcı is a scholar working on Rheumatology, Ophthalmology and Hematology.
According to data from OpenAlex, Yusuf Yazıcı has authored 237 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Rheumatology, 51 papers in Ophthalmology and 38 papers in Hematology. Recurrent topics in Yusuf Yazıcı's work include Rheumatoid Arthritis Research and Therapies (111 papers), Systemic Lupus Erythematosus Research (54 papers) and Ocular Diseases and Behçet’s Syndrome (51 papers). Yusuf Yazıcı is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (111 papers), Systemic Lupus Erythematosus Research (54 papers) and Ocular Diseases and Behçet’s Syndrome (51 papers). Yusuf Yazıcı collaborates with scholars based in United States, Türkiye and France. Yusuf Yazıcı's co-authors include Theodore Pincus, Martin Bergman, Hasan Yazıcı, Gülen Hatemi, Christopher J. Swearingen, Tuulikki Sokka, Doruk Erkan, Emire Seyahi, Steven B. Abramson and Stephen A. Paget and has published in prestigious journals such as New England Journal of Medicine, Advanced Drug Delivery Reviews and The FASEB Journal.
In The Last Decade
Yusuf Yazıcı
222 papers receiving 5.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yusuf Yazıcı United States | 43 | 4.2k | 1.5k | 1.2k | 766 | 643 | 237 | 6.1k | ||
| Florenzo Iannone Italy | 42 | 3.3k 0.8× | 1.1k 0.7× | 1.2k 1.0× | 735 1.0× | 1.4k 2.2× | 349 | 6.8k | ||
| Mauro Galeazzi Italy | 49 | 3.8k 0.9× | 1.2k 0.8× | 1.2k 1.1× | 661 0.9× | 1.9k 2.9× | 199 | 7.9k | ||
| Pilar Brito‐Zerón Spain | 47 | 3.3k 0.8× | 1.1k 0.8× | 317 0.3× | 1.1k 1.5× | 1.9k 2.9× | 120 | 8.8k | ||
| Sedat Kiraz Türkiye | 32 | 1.2k 0.3× | 586 0.4× | 603 0.5× | 889 1.2× | 719 1.1× | 195 | 3.9k | ||
| E. Martín‐Mola Spain | 44 | 4.2k 1.0× | 1.5k 1.0× | 238 0.2× | 234 0.3× | 1.6k 2.4× | 113 | 6.0k | ||
| Fabrizio Cantini Italy | 51 | 4.8k 1.1× | 1.0k 0.7× | 705 0.6× | 3.1k 4.1× | 1.8k 2.8× | 173 | 7.6k | ||
| Benjamín Fernández‐Gutiérrez Spain | 36 | 2.4k 0.6× | 391 0.3× | 284 0.2× | 951 1.2× | 1.2k 1.9× | 194 | 4.9k | ||
| Mary Chester Wasko United States | 33 | 3.4k 0.8× | 1.2k 0.8× | 170 0.1× | 254 0.3× | 976 1.5× | 64 | 5.0k | ||
| Raimón Sanmartí Spain | 40 | 3.6k 0.9× | 1.3k 0.9× | 161 0.1× | 383 0.5× | 1.6k 2.5× | 263 | 5.3k | ||
| Santos Castañeda Spain | 38 | 3.1k 0.7× | 489 0.3× | 152 0.1× | 1.0k 1.4× | 1.2k 1.9× | 298 | 5.6k |
Countries citing papers authored by Yusuf Yazıcı
Since
Specialization
Citations
This map shows the geographic impact of Yusuf Yazıcı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuf Yazıcı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuf Yazıcı more than expected).
Fields of papers citing papers by Yusuf Yazıcı
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yusuf Yazıcı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuf Yazıcı. The network helps show where Yusuf Yazıcı may publish in the future.
Co-authorship network of co-authors of Yusuf Yazıcı
This figure shows the co-authorship network connecting the top 25 collaborators of Yusuf Yazıcı. A scholar is included among the top collaborators of Yusuf Yazıcı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuf Yazıcı. Yusuf Yazıcı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yazıcı, Yusuf, J. Tambiah, Christopher J. Swearingen, et al.. (2024). Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study. Clinical and Experimental Rheumatology. 43(5). 854–860.
2.
Yazıcı, Yusuf, J. Tambiah, Christopher J. Swearingen, et al.. (2024). A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients. Clinical and Experimental Rheumatology. 43(5). 847–853.
3.
Yazıcı, Yusuf, et al.. (2024). POS1177 TREATMENT WITH LORECIVIVINT LEADS TO IMPROVED LONG-TERM PATIENT ACCEPTABLE SYMPTOM STATE (PASS) COMPARED TO PLACEBO: DATA FROM PHASE 3 EXTENSION TRIAL. Annals of the Rheumatic Diseases. 83. 670–671.
4.
Hatemi, Gülen, Didar Uçar, Uğur Uygunoğlu, Hasan Yazıcı, & Yusuf Yazıcı. (2023). Behçet Syndrome. Rheumatic Disease Clinics of North America. 49(3). 585–602.
5.
Fineman, Mark, Timothy E. McAlindon, Christian Lattermann, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study. Rheumatology and Therapy. 10(6). 1741–1752.
6.
Hatemi, Gülen, Alexa Meara, Yeşim Özgüler, et al.. (2020). Core Set of Domains for Outcome Measures in Behçet's Syndrome. Arthritis Care & Research. 74(4). 691–699.
7.
Deshmukh, V., Carine Bossard, T. Seo, et al.. (2019). SM04690, A potential disease-modifying treatment for knee osteoarthritis, functions through inhibition of CLK2 and DYRK1A, novel molecular regulators of Wnt signaling, chondrogenesis, and inflammation. Osteoarthritis and Cartilage. 27. S37–S37.
8.
Turkstra, Franktien, et al.. (2018). Adherence to guidelines for the treatment of Behçet's syndrome in New York and Amsterdam.. PubMed. 35 Suppl 108(6). 55–59.
9.
Deshmukh, V., et al.. (2018). Experimental tendinopathy treatment with SM04755, a topical small molecule inhibitor of the WNT pathway. Osteoarthritis and Cartilage. 26. S24–S24.
10.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2018). Results from a 52-week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis. Osteoarthritis and Cartilage. 26. S293–S294.
11.
Nikiphorou, Elena, James Galloway, Piet L. C. M. van Riel, et al.. (2017). The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.. PubMed. 35(3). 477–483.
12.
Çınar, Muhammet, Sedat Yılmaz, Fatma İlknur Çınar, et al.. (2015). A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis. Rheumatology International. 35(9). 1575–1580.
13.
Adamson, Rosemary, et al.. (2013). Fatal Acute Necrotizing Eosinophilic Myocarditis Temporally Related to Use of Adalimumab in a Patient With Relapsing Polychondritis. JCR Journal of Clinical Rheumatology. 19(7). 386–389.
14.
Béresniak, Ariel, Jürgen Braun, Paolo Angelo Cortesi, et al.. (2012). Treat-to-Target in Rheumatoid Arthritis: Clinical and PharmacoEconomic Considerations. Clinical and Experimental Rheumatology. 30.
15.
Swearingen, Christopher J., et al.. (2012). Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care. BMJ Open. 2(5). e001117–e001117.
16.
Pincus, Theodore, P. Hines, Martin Bergman, et al.. (2011). Proposed Severity and Response Criteria for Routine Assessment of Patient Index Data (RAPID3): Results for Categories of Disease Activity and Response Criteria in Abatacept Clinical Trials. The Journal of Rheumatology. 38(12). 2565–2571.
17.
Yazıcı, Yusuf, et al.. (2004). Effect of Glucose Insulin Potassium Infusion on Myocardial Injury and Endothelin-1 Levels in Chronic Ischemic Heart Failure. Archives of the Turkish Society of Cardiology. 32(2). 99–106.
18.
Yazıcı, Yusuf, et al.. (2004). Heart Rate Variability and QT Dispersion in Patients with Slow Coronary Flow. Archives of the Turkish Society of Cardiology. 32(1). 10–15.
19.
Yazıcı, Yusuf, et al.. (2004). Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Annals of the Rheumatic Diseases. 64(2). 207–211.
20.
Yazıcı, Yusuf, Karen Onel, & Lisa R. Sammaritano. (2000). Neonatal lupus erythematosus in triplets.. The Journal of Rheumatology. 27(3). 807–9.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Florenzo Iannone Breakdown of academic impact, for papers by Mauro Galeazzi Breakdown of academic impact, for papers by Pilar Brito‐Zerón Breakdown of academic impact, for papers by Sedat Kiraz Breakdown of academic impact, for papers by E. Martín‐Mola Breakdown of academic impact, for papers by Fabrizio Cantini Breakdown of academic impact, for papers by Benjamín Fernández‐Gutiérrez Breakdown of academic impact, for papers by Mary Chester Wasko Breakdown of academic impact, for papers by Raimón Sanmartí Breakdown of academic impact, for papers by Santos Castañeda